Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2002

View Archived Issues

Amsalog well tolerated at oral doses up to 1600 mg/m2 in cancer patients

Pantoprazole safely eliminates gastrointestinal bleeding in patient with short bowel syndrome

Barr to acquire Enhance assets and liabilities

Genome Therapeutics updates achievements in 2001

NX-1207 shows efficacy in preclinical studies for treatment of benign prostatic hyperplasia

Ivax completes pilot phase II study of E2CDS in postmenopausal women

Novel antibiotic for acne enters phase I testing

Phase II trial for ISIS-14803 in hepatitis C commences

Array BioPharma and Japan Tobacco to develop small-molecule therapeutics

Licensing opportunity from NIH: use of CpG oligodeoxynucleotides to promote angiogenesis

PTH2 receptors for treatment of chronic pain available for licensing from NIH

rNAPc2 safe and effective in phase IIa trial in patients undergoing PCI

Cognitive function improved by NS-2330 in normal subjects and those with possible AD

Nonopiate analgesic provides significant and rapid dental pain relief after intranasal dosing

AHP changes name to Wyeth

Roche's MabThera and Xeloda cleared for new indications in Europe

Potent marine neurotoxin advances towards clinical trials in pain and opiate withdrawal

NeuroSearch and Ferrer discontinue development of NS-2710 for treatment of anxiety

Novel cancer therapy now available in U.S.

Novel antitussive agents in the Dompe pipeline

Virocell designs new vanadium compounds which potentiate effects of anti-HIV agents

Selective small-molecule inhibitors of ErbB-2 kinase discovered at Georgetown

Antitumor lipid-peptide conjugates claimed by Indian research group

Inhibitors of iNOS claimed by AstraZeneca for inflammatory disorders and pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...